April 20 (Reuters) - Teva Pharmaceutical Industries Ltd on Thursday launched an asthma inhaler that will be the first direct competition to GlaxoSmithKline's best-selling Advair. Teva, which won U.S.

LONDON (Reuters) - Generic drugmakers, hoping for rich pickings from the launch of copies of GlaxoSmithKline's best-selling Advair inhaler in the United States next year, say they can win business ...

The first generic version of the popular Advair asthma inhaler has been approved by U.S. regulators. The Food and Drug Administration on Wednesday approved Mylan’s version in three strengths for ages ...

LONDON, Jan 30 (Reuters) - Israel's Teva Pharmaceutical Industries has won U.S. approval to market a copy of GlaxoSmithKline's best-selling Advair inhaler, although the real battle is still to come.

The Pfizer-Mylan deal would give the latter the rights to develop and sell Pfizer's generic version of Advair, which uses a proprietary dry-powder inhaler, just as GSK's Advair Diskus does. Mylan will ...

Signage is pictured on the company headquarters of GlaxoSmithKline in west London July 21, 2008. GlaxoSmithKline announce their half yearly results on Wednesday July 23. REUTERS/Toby Melville By Ben ...